Difference between revisions of "Obinutuzumab (Gazyva)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chronic lymphocytic leukemia (CLL/SLL) medications" to "Category:Chronic lymphocytic leukemia medications") |
Warner-admin (talk | contribs) m (Text replacement - "[[Chronic lymphocytic leukemia (CLL/SLL)" to "[[Chronic lymphocytic leukemia") |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Chronic lymphocytic leukemia | + | *[[Chronic lymphocytic leukemia]] |
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11/1/2013: Granted FDA approval for use [[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)#Chlorambucil_.26_Obinutuzumab_.28GClb.29|in combination with chlorambucil]] for the treatment of patients with previously untreated [[Chronic lymphocytic leukemia | + | *11/1/2013: Granted FDA approval for use [[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)#Chlorambucil_.26_Obinutuzumab_.28GClb.29|in combination with chlorambucil]] for the treatment of patients with previously untreated [[Chronic lymphocytic leukemia | chronic lymphocytic leukemia (CLL)]]. |
*2/26/2016: FDA approval expanded "for use [[Follicular_lymphoma#Bendamustine_.26_Obinutuzumab|in combination with bendamustine]] followed by [[Follicular_lymphoma#Obinutuzumab_monotherapy_3|obinutuzumab monotherapy]] for the treatment of patients with [[Follicular lymphoma|follicular lymphoma (FL)]] who relapsed after, or are refractory to, a [[Rituximab (Rituxan)|rituximab-containing]] regimen." | *2/26/2016: FDA approval expanded "for use [[Follicular_lymphoma#Bendamustine_.26_Obinutuzumab|in combination with bendamustine]] followed by [[Follicular_lymphoma#Obinutuzumab_monotherapy_3|obinutuzumab monotherapy]] for the treatment of patients with [[Follicular lymphoma|follicular lymphoma (FL)]] who relapsed after, or are refractory to, a [[Rituximab (Rituxan)|rituximab-containing]] regimen." | ||
*11/16/2017: Granted regular FDA approval " in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV [[Follicular lymphoma|follicular lymphoma (FL)]]." | *11/16/2017: Granted regular FDA approval " in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV [[Follicular lymphoma|follicular lymphoma (FL)]]." | ||
Revision as of 18:25, 31 July 2019
General information
Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody. Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region, which is postulated to enhance its immunomodulatory effect.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.[1]
Diseases for which it is used
Patient drug information
No information available.
History of changes in FDA indication
- 11/1/2013: Granted FDA approval for use in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
- 2/26/2016: FDA approval expanded "for use in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen."
- 11/16/2017: Granted regular FDA approval " in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL)."
Also known as
- Code names: GA101, R7159, RO5072759
- Generic name: afutuzumab
- Brand name: Gazyva